Cardiac Science Predecessors Named To Deloitte’s Technology Fast 50, Fast 500

BOTHELL, Wash., Oct. 20 /PRNewswire-FirstCall/ -- Cardiac Science Corporation , a global leader in advanced diagnostic cardiology and automated external defibrillation products, announced today that its predecessor companies have been individually recognized by Deloitte's Technology Fast 50 Program, a ranking of the 50 fastest growing technology companies in a given area, and to the 2005 Deloitte Technology Fast 500, a ranking of the 500 fastest growing technology companies in North America, by Deloitte & Touche LLP, one of the nation's leading professional services firms.

(Logo: http://www.newscom.com/cgi-bin/prnh/20050913/SFTU139LOGO )

Cardiac Science, Inc. was ranked number 5 in Orange County, CA, with a five-year growth rate of 1,515% and Quinton Cardiology Systems, Inc. was ranked number 35 in Washington State, with a five-year growth rate of 77%.

In addition, Cardiac Science, Inc. was ranked 136th on the Deloitte Technology Fast 500, a ranking of technology companies throughout North America.

Rankings are based on cumulative revenue growth percentages over the five year period from 2000 through 2004. Quinton Cardiology Systems, Inc. and Cardiac Science, Inc. merged to form Cardiac Science Corporation on September 1, 2005.

"We believe the historic growth of our predecessor companies lays a strong foundation for the future of the new Cardiac Science Corporation, and we are pleased that they were recognized by the 2005 Technology Fast 50 and Technology Fast 500 programs," said President and Chief Executive Officer John Hinson.

About Deloitte

Deloitte refers to one or more of Deloitte Touche Tohmatsu, a Swiss Verein, its member firms and their respective subsidiaries and affiliates. As a Swiss Verein (association), neither Deloitte Touche Tohmatsu nor any of its member firms has any liability for each other's acts or omissions. Each of the member firms is a separate and independent legal entity operating under the names "Deloitte," "Deloitte & Touche," "Deloitte Touche Tohmatsu" or other related names. Services are provided by the member firms or their subsidiaries or affiliates and not by the Deloitte Touche Tohmatsu Verein.

Deloitte & Touche USA LLP is the US member firm of Deloitte Touche Tohmatsu. In the US, services are provided by the subsidiaries of Deloitte and Touche USA LLP (Deloitte & Touche LLP, Deloitte Consulting LLP, Deloitte Financial Advisory Services LLP, Deloitte Tax LLP and their subsidiaries), and not by Deloitte & Touche USA LLP.

About Cardiac Science Corporation

Cardiac Science Corporation develops, manufactures, and markets a family of advanced diagnostic and therapeutic cardiology devices and systems, including automated external defibrillators, electrocardiographs, stress test systems, Holter monitoring systems, hospital defibrillators, cardiac rehabilitation telemetry systems, patient monitor - defibrillators and cardiology data management systems. Cardiac Science Corporation also sells a variety of related products and consumables, and provides a comprehensive portfolio of training, maintenance and support services.

The company is the successor to various entities that have owned and operated cardiology related businesses, which sold products under the trusted brand names Burdick(R), Powerheart(R), and Quinton(R). Cardiac Science Corporation is headquartered in Bothell, WA, and also has operations in Lake Forest, California, Deerfield, Wisconsin, Shanghai, China, Copenhagen, Denmark and Manchester, United Kingdom.

Contact Mike Matysik Senior vice president and chief financial officer 425-402-2009 Forward Looking Statements

This press release contains forward-looking statements, including, but not limited to, those relating to Cardiac Science Corporation's future revenue growth and profitability that involve a number of risks and uncertainties. These are forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "intend," anticipate," variations of such words, and similar expressions identify forward-looking statements, but their absence does not mean that the statement is not forward-looking. Actual results may vary significantly from the results expressed or implied in such statements. Factors that could cause or contribute to such varying results and other risks are more fully described in the registration statement on Form S-4/A that was filed by Cardiac Science Corporation under the name CSQ Holding Company on July 28, 2005, under the caption "Risk Factors," and in the Annual Reports of Quinton Cardiology Systems, Inc. and Cardiac Science, Inc. on Form 10-K for the year ended December 31, 2004, under the captions "Certain Factors that May Affect Future Results" and in other documents, we file with the Securities and Exchange Commission. Cardiac Science Corporation undertakes no duty or obligation to update the information provided herein.

CONTACT: Mike Matysik, Senior vice president and chief financial officerof Cardiac Science Corporation, +1-425-402-2009

Web site: http://www.cardiacscience.com/